Ulcerative colitis (UC) is one of the most prevalent forms of inflammatory bowel disease, affecting millions of patients globally. Characterized by chronic inflammation of the colon's inner lining, UC causes debilitating symptoms including diarrhea, abdominal cramping, rectal bleeding, and fatigue. With approximately 3.2 million diagnosed cases across major markets in 2024 — and 60% classified as moderate to severe — the urgency for effective, targeted treatment has never been higher. The good news? The pharmaceutical pipeline is more active than ever, with breakthrough therapies redefining what is possible for UC patients.
What Is the Best Medicine for Ulcerative Colitis?
Best medicine for ulcerative colitis is not a one-size-fits-all answer — it depends on disease severity, prior treatment history, and patient-specific factors. Currently, treatment is organized into six broad classes: conventional therapies such as aminosalicylates and corticosteroids, biologics including anti-TNF agents and integrin inhibitors, IL-23 inhibitors, S1P-receptor modulators, JAK inhibitors, and emerging novel mechanisms like LANCL2 protein stimulators and miR-124 enhancers. FDA-approved options include well-known names such as HUMIRA, ENTYVIO, STELARA, RINVOQ, ZEPOSIA, SKYRIZI, OMVOH, TREMFYA, and VELSIPITY, among others.
New Ulcerative Colitis Drug Making Headlines
The most talked-about new ulcerative colitis drug in recent years is SKYRIZI (risankizumab) by AbbVie, which received FDA approval in June 2024 for moderately to severely active UC — becoming the first IL-23 inhibitor approved for both ulcerative colitis and Crohn's disease. Following a 12-week induction period, patients can self-administer the drug at home using a user-friendly on-body injector. Just months after launch, SKYRIZI had already captured double the market share of its closest competitor, reflecting strong physician and patient confidence in this therapy.
New Medications for Ulcerative Colitis: A Diverse Pipeline
New medications for ulcerative colitis are advancing through clinical trials at a remarkable pace. Over 70 pharmaceutical companies are now actively developing more than 75 pipeline therapies, spanning multiple novel mechanisms of action. Highlights include:
TREMFYA (guselkumab) by Janssen — an IL-23 inhibitor that received FDA approval in September 2024, now competing directly with SKYRIZI in the IBD market.
Obefazimod (ABX464) by Abivax — an oral miR-124 enhancer in Phase III with top-line data expected in 2025 and an NDA submission planned for early 2026.
Tulisokibart (MK-7240) by Merck — a TL1A-targeting monoclonal antibody in Phase III demonstrating strong Phase II remission results.
MORF-057 by Eli Lilly — an oral α4β7 integrin inhibitor in Phase II, offering a potential pill-based alternative to vedolizumab.
Omilancor (BT-11) by Landos Biopharma/NImmune — a gut-restricted LANCL2 stimulator achieving clinical remission in over 30% of patients in recent trials.
New Medication for Ulcerative Colitis: The Shift to Oral Therapies
A defining trend among new medication for ulcerative colitis development is the push toward orally administered options. Drugs like RINVOQ (upadacitinib), ZEPOSIA (ozanimod), VELSIPITY (etrasimod), and emerging candidates such as TAK-279 and MORF-057 represent a growing preference for once-daily pills over infusions and injections. Physicians and patients alike are gravitating toward oral IBD therapies due to their convenience, ease of use, and improved adherence profiles.
New Drug for Ulcerative Colitis: Biosimilar Competition Intensifying
Alongside innovative therapies, the new drug for ulcerative colitis landscape is also being reshaped by biosimilar competition. STELARA (ustekinumab), once a cornerstone of biologic treatment, now faces multiple biosimilar challenges — including STEQEYMA, WEZLANA, and YESINTEK — approved in the US and EU between 2024 and 2025. This is expected to significantly broaden patient access to advanced biologic therapy while driving down costs across the treatment ecosystem.
Is There a Permanent Cure for Ulcerative Colitis?
Many patients ask about a permanent cure for ulcerative colitis. Currently, surgery (colectomy) remains the only definitive cure, but it is reserved for severe or refractory cases. Medically, the goal is sustained remission — keeping the disease quiet and preventing flares over the long term. The new generation of targeted biologics and small molecules is bringing more patients closer to this goal than ever before, with Phase III data showing durable remission rates exceeding 70% at nearly two years of follow-up for leading candidates.
Medication for Ulcerative Colitis: Matching Therapy to the Patient
Selecting the right medication for ulcerative colitis requires careful consideration of factors such as disease extent and severity, prior biologic or JAK inhibitor exposure, infection risk profile, and patient lifestyle preferences. The expanding toolkit now gives gastroenterologists the ability to personalize treatment plans with greater precision — a critical shift from the earlier era of broad immunosuppression with significant side-effect burdens.
New Treatment for Ulcerative Colitis: Beyond Inflammation Control
New treatment for ulcerative colitis strategies are evolving beyond simply controlling inflammation. Emerging approaches include mesenchymal stem cell therapy (Remestemcel-L by Mesoblast Ltd.), microbiome-targeting agents, and precision biomarker-driven treatment selection. These innovations reflect a deeper understanding of the immunological mechanisms underlying UC and promise to unlock entirely new categories of therapeutic benefit for patients who have failed conventional and advanced therapies.
New Treatment for Ulcerative Colitis 2024: Key Milestones
New treatment for ulcerative colitis 2024 was defined by several pivotal regulatory and clinical milestones. SKYRIZI's FDA approval in June 2024 was the headline event, followed by TREMFYA's FDA approval in September 2024 for adult UC. Eli Lilly completed its acquisition of Morphic Holding in August 2024, bringing MORF-057 into its gastroenterology pipeline. Multiple STELARA biosimilars also received regulatory green lights, collectively marking 2024 as one of the most transformative years the UC market has seen in over a decade.
New Medicine for Ulcerative Colitis: What's Coming Next
The pipeline for new medicine for ulcerative colitis through 2025–2027 is exceptionally rich. Obefazimod's NDA submission is targeted for early 2026, while Omilancor aims for FDA submission by 2027. Sanofi's SAR441566, Roche's emerging candidates, and AbbVie's ABBV-668 are among the next wave of therapies expected to enter late-stage evaluation. With the UC market projected to grow substantially through 2034, driven by rising diagnosis rates and expanding therapeutic options, the outlook for patients has never been more promising.
The Road Ahead
Ulcerative colitis management is undergoing a profound transformation. From highly targeted biologics and precision small molecules to biosimilar-driven access improvements and stem cell therapies on the horizon, the treatment landscape is richer, more diverse, and more patient-centered than at any point in history. For patients and caregivers navigating this evolving space, staying informed about emerging options is more important — and more rewarding — than ever.
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact us
Kanishk
Comments